

Figure 2 Survival curves stratified by EGFR expression in (A) IHCC and (B) EHCC (Kaplan–Meier method). The outcome of EGFR-positive cases was significantly worse than that of EGFR-negative cases in both IHCC ($P=0.0008$) and EHCC ($P=0.0204$) (by log-rank test).

95% CI, 1.05–3.39; $P=0.0335$), along with intrahepatic metastasis (HR, 2.36; 95% CI, 1.31–4.25; $P=0.0044$), lymph node metastasis (HR, 2.24; 95% CI, 1.19–4.22; $P=0.0126$), and venous invasion (HR, 6.74; 95% CI, 1.31–34.73; $P=0.0225$), whereas, in EHCC, lymph node metastasis (HR, 1.75; 95% CI, 1.03–2.98; $P=0.0394$) and dissected periductal structures margin (HR, 1.81; 95% CI, 1.03–3.16; $P=0.0383$) were independent risk factors of tumour recurrence, but EGFR expression was not associated with tumour recurrence even in univariate analysis.

DISCUSSION

This study, analysing EGFR/VEGF/HER2 expression in the largest cohort of cholangiocarcinoma reported so far, showed for the first time that EGFR expression in IHCC is significantly associated with poor prognosis. In addition, our study confirmed previously reported prognostic factors in cholangiocarcinoma, such as macroscopic type, intrahepatic metastasis, lymph node metastasis, and histological classification (Yamamoto *et al*, 1998; Ohtsuka *et al*, 2002; Morimoto *et al*, 2003; DeOliveira *et al*, 2007). Expression of EGFR or HER2 is known to be a prognostic factor in some cancers (Gusterson *et al*, 1992; Nicholson *et al*, 2001), but no previous study has clarified the influence of these molecules on prognosis in cholangiocarcinoma (Ito *et al*, 2001; Altimari *et al*, 2003; Nakazawa *et al*, 2005), probably because cholangiocarcinoma is a relatively rare cancer and collection of a large cohort is difficult. Indeed, most previous studies were performed on the basis of only 50 cases at most. Although it is unclear why EGFR expression in IHCC is an independent prognostic factor, it may be associated with frequent relapse of cancer because EGFR expression is also a risk factor for tumour recurrence.

Table 3 Multivariate analyses regarding overall survival and tumour recurrence in IHCC (Cox’s proportional hazard model)

	Overall survival			Tumour recurrence		
	HR	95% CI	P-value	HR	95% CI	P-value
<i>Macroscopic type</i>						
Non-mass forming	1.00			1.00		
Mass forming	2.96	1.06–8.31	0.0390	3.06	1.00–9.40	0.0505
<i>Invasion of portal vein</i>						
Negative	1.00			1.00		
Positive	0.67	0.30–1.47	0.31	1.01	0.43–2.41	0.98
<i>Invasion of hepatic vein</i>						
Negative	1.00			1.00		
Positive	1.19	0.66–2.12	0.57	1.17	0.65–2.14	0.60
<i>Intrahepatic metastasis</i>						
Negative	1.00			1.00		
Positive	2.91	1.60–5.29	0.0005	2.36	1.31–4.25	0.0044
<i>Lymph node metastasis</i>						
Negative	1.00			1.00		
Positive	1.96	1.04–3.69	0.0375	2.24	1.19–4.22	0.0126
<i>Histological classification</i>						
Well differentiated	1.00			1.00		
Moderately differentiated	1.24	0.56–2.75	0.60	0.65	0.28–1.53	0.32
Poorly differentiated	2.09	0.58–7.49	0.26	1.35	0.32–5.72	0.69
<i>Lymphatic vessel invasion</i>						
Negative	1.00			1.00		
Positive	3.31	0.80–13.65	0.0982	1.37	0.41–4.56	0.61
<i>Venous invasion</i>						
Negative	1.00			1.00		
Positive	4.07	0.97–17.09	0.0551	6.74	1.31–34.73	0.0225
<i>Perineural invasion</i>						
Negative	1.00			—		
Positive	0.60	0.26–1.36	0.22	—		
<i>Bile duct margin</i>						
Negative	1.00			—		
Positive	1.84	0.91–3.73	0.0923	—		
<i>EGFR expression</i>						
Negative	1.00			1.00		
Positive	2.67	1.52–4.69	0.0006	1.89	1.05–3.39	0.0335

Abbreviations: CI = confidence interval; HR = hazard ratio.

In contrast to IHCC, EGFR expression was not an independent prognostic factor in EHCC, but was associated with clinical features that may represent tumour progression and invasion, such as lymph node metastasis and apparent stromal invasion in EHCC. Because cancer tissue tends to be heterogeneous, histological diagnosis is generally decided on the basis of the degree of differentiation that predominates. In order to elucidate the biological significance of each protein, we microscopically examined positive cases in detail and compared their expression with histological components, and found that EGFR tended to be expressed in the poorly differentiated component, which is characterised by infiltration in both IHCC and EHCC. Similar results have been reported in bladder cancer (Neal *et al*, 1985), oesophageal adenocarcinoma (Wilkinson *et al*, 2004), and IHCC (Ito *et al*, 2001), although the studies were based on small cohorts. These findings indicate that EGFR expression may be a relatively late event in the development of cholangiocarcinoma and

Table 4 Multivariate analyses regarding overall survival and tumour recurrence in EHCC (Cox's proportional hazard model)

	Overall survival			Tumour recurrence		
	HR	95% CI	P-value	HR	95% CI	P-value
<i>Tumour size</i>						
≤3.0 cm	1.00			—		
>3.0 cm	1.29	0.71–2.35	0.41	—	—	—
<i>Macroscopic type</i>						
Polypoid	1.00			—		
Non-polypoid	0.44	0.16–1.26	0.13	—	—	—
<i>Depth of tumour invasion</i>						
Within FM	1.00			1.00		
Beyond FM	1.26	0.19–8.60	0.81	1.16	0.24–5.57	0.85
<i>Invasion of portal vein</i>						
Negative	1.00			1.00		
Positive	1.48	0.81–2.69	0.20	1.59	0.92–2.75	0.94
<i>Lymph node metastasis</i>						
Negative	1.00			1.00		
Positive	2.03	1.16–3.55	0.0133	1.75	1.03–2.98	0.0394
<i>Histological classification</i>						
Papillary	1.00			1.00		
Well differentiated	3.40	0.85–13.66	0.0849	0.91	0.33–2.51	0.85
Moderately differentiated	4.23	1.08–16.50	0.0380	1.19	0.47–3.02	0.72
Poorly differentiated	13.22	3.10–56.45	0.0005	2.80	0.99–7.87	0.0516
<i>Lymphatic vessel invasion</i>						
Negative	1.00			1.00		
Positive	1.78	0.29–11.10	0.54	2.36	0.45–12.37	0.31
<i>Venous invasion</i>						
Negative	1.00			1.00		
Positive	3.93	0.81–19.12	0.0898	1.89	0.52–6.92	0.34
<i>Perineural invasion</i>						
Negative	1.00			1.00		
Positive	1.94	0.58–6.53	0.29	0.98	0.38–2.51	0.97
<i>Dissected periductal structures margin</i>						
Negative	1.00			1.00		
Positive	1.20	0.67–2.17	0.54	1.81	1.03–3.16	0.0383
<i>Invasion to other organ</i>						
Negative	1.00			1.00		
Positive	1.02	0.53–1.94	0.96	0.94	0.53–1.69	0.84
<i>EGFR expression</i>						
Negative	1.00			—		
Positive	1.04	0.55–1.96	0.90	—	—	—

HR = hazard ratio; CI = confidence interval; FM = fibromuscular layer.

associated with invasion and progression. Because it has been previously reported that poor differentiation is associated with unfavourable outcome in other cancers (Sohn *et al*, 2000; Hassan *et al*, 2005), the association between EGFR expression and poor differentiation may also be a reason that EGFR expression is a prognostic factor.

Though the prognostic factors were different between IHCC and EHCC, it may be due to the difference of anatomical character, which extrahepatic bile duct is near from other organs and is not surrounded by liver parenchyma in contrast to intrahepatic bile duct. The intrahepatic epithelium is distinct from the extrahepatic epithelium in terms of development and differentiation (Shiojiri, 1997), and the risk factors, pathogenesis,

and clinical features of IHCC and EHCC are different (Strom *et al*, 1985; Nakeeb *et al*, 1996; Shaib *et al*, 2007). Although no previous studies have elucidated EGFR function in normal bile duct epithelium, EGFR overexpression might play distinct roles in IHCC and EHCC.

Vascular endothelial growth factor expression was detected frequently, being evident in about 60% of our study cases, which is consistent with previous studies (31.4–75.6%) (Hida *et al*, 1999; Tang *et al*, 2006). Our study revealed that VEGF expression was significantly associated with intrahepatic metastasis in IHCC. Vascular endothelial growth factor is a key molecule in angiogenic pathway. Angiogenesis is an essential component in the process of metastasis, and this has been partly confirmed by studies showing that microvessel density (MVD) is associated with metastasis and a poorer outcome in a range of cancers (Weidner *et al*, 1991; Zetter, 1998). It has also been reported that high MVD is an independent prognostic factor in node-negative IHCC (Shirabe *et al*, 2004) and is associated with VEGF expression in IHCC (Tang *et al*, 2006), although no study has clarified the involvement of angiogenesis in the process of metastasis in cholangiocarcinoma. Our result suggests that VEGF plays an important role in the process of cholangiocarcinoma metastasis by promoting angiogenesis.

Human epidermal growth factor receptor 2 was expressed in only 11 of 130 EHCC cases (8.5%) and in one of 106 IHCC cases (0.9%). The proportion of HER2-positive cases reported previously has varied from 4.2 to 81.8% (Ito *et al*, 2001; Aishima *et al*, 2002; Ukita *et al*, 2002; Altimari *et al*, 2003; Nakazawa *et al*, 2005), and the discrepancy may be due to differences in staining procedure or tumour location. In contrast to EGFR expression, HER2 expression was associated with more favourable clinical features, such as a polypoid macroscopic type and absence of other organ involvement. The proportion of HER2-positive cases in papillary adenocarcinoma was higher than in other histological types, consistent with some previous reports claiming that HER2 expression in cholangiocarcinoma is associated with an early disease stage (Endo *et al*, 2002; Nakazawa *et al*, 2005). Microscopically, HER2 is preferentially expressed in well differentiated component, and it is also expressed in dedifferentiated components (moderately and/or poorly differentiated components) in progressive cases. This indicates that HER2 overexpression is maintained from an early stage of carcinogenesis in cases that are HER2-positive.

Recently, the efficacy of molecular targeting therapy for various molecules including EGFR/VEGF/HER2 has been proved clinically in a wide range of cancers. Epidermal growth factor receptor inhibitor has been reported to be effective in a cholangiocarcinoma cell line (Yoon *et al*, 2004), and a phase II study of erlotinib, an EGFR inhibitor, in patients with advanced biliary cancer has been reported. In this study, the progression-free rate at 6 months as a primary end point was 17% (7/42) despite the fact that disease condition was severe, and the disease control rate was 50% (20/42) (Philip *et al*, 2006). This study suggested the clinical applicability of the EGFR inhibitor to cholangiocarcinoma. Several clinical trials demonstrating the efficacy of VEGF inhibition for other cancers have been reported (Hurwitz *et al*, 2004; Sandler *et al*, 2006), and VEGF upregulation in tumour cells is considered to be a mechanism of resistance to EGFR inhibitors (Viloria Petit *et al*, 2001). Therefore, dual inhibition of both EGFR and VEGF may exert a synergistic effect.

In summary, we have shown that EGFR and VEGF expression is relatively common in cholangiocarcinoma. Moreover, in IHCC, EGFR expression is an independent prognostic factor and VEGF expression is associated with intrahepatic metastasis. In EHCC, EGFR expression is associated with clinical factors involved in tumour progression and invasion. Our results suggest the validity and significance of molecular targeting agents for EGFR and/or VEGF pathway, and that further preclinical and clinical studies are warranted for improving the clinical outcome of cholangiocarcinoma.

ACKNOWLEDGEMENTS

This work was supported in part by Foundation for Promotion of Cancer Research (FPCR), Japan, grant-in-aid for the Comprehensive 10-Year-Strategy for Cancer Control from the Ministry of Health, Labor and Welfare, Japan and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute

of Biomedical Innovation (NiBio), Japan. DY is a recipient of a Research Resident Fellowship from FPCR.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

REFERENCES

- Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M (2002) c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. *Histopathology* 40(3): 269–278
- Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF (2003) Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. *Dig Liver Dis* 35(5): 332–338
- DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. *Ann Surg* 245(5): 755–762
- Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breaux JL, Perret GY (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. *Br J Cancer* 94(12): 1823–1832
- Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE (2002) ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. *Hepatology* 36(2): 439–450
- Gonzalez Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. *Oncologist* 11(8): 857–867
- Gusterson BA, Gelber RD, Goldhirsch A, Price KN, S ave-S oderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Thorstoft J, Grigolato P, Bettelheim R, Neville AM, B urki K, Castiglione M, Collins J, Lindtner J, Senn HJ (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study group. *J Clin Oncol* 10(7): 1049–1056
- Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. *J Cancer Res Clin Oncol* 131: 649–652
- Hamilton SR, Altonen LA (2000) *World Health Organization Classification of Tumours: pathology & Genetics: Tumours of the Digestive System*. Lyon: IARC Press
- Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ, Landreneau RJ (2001) Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. *Ann Surg Oncol* 8(1): 72–79
- Hassan C, Zullo A, Risio M, Rossini FP, Morini S (2005) Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. *Dis Colon Rectum* 48(8): 1588–1596
- Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, Nagashima K, Katoh H (1999) Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. *Anticancer Res* 19(3B): 2257–2260
- Huang TW, Wang CH, Hsieh CB (2007) Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. *Onkologie* 30(3): 129–131
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350(23): 2335–2342
- Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Higashiyama S, Monden M, Matsuura N (2001) Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. *Pathol Res Pract* 197(2): 95–100
- Khan SA, Thomas HC, Davidson BR, Taylor Robinson SD (2005) Cholangiocarcinoma. *Lancet* 366(9493): 1303–1314
- Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. *Clin Cancer Res* 12: 1680–1685
- Liver Cancer Study Group of Japan (2003) *General Rules for the Clinical and Pathological Study of Primary Liver Cancer*, 2nd English edn. Tokyo: Kanehara & Co. LTD
- Mohammed RA, Green A, El Shikh S, Paish EC, Ellis IO, Martin SG (2007) Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. *Br J Cancer* 96(7): 1092–1100
- Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, Fujikawa M, Ito T, Yamamoto S, Kitagawa T (2003) Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. *J Hepatobiliary Pancreat Surg* 10(6): 432–440
- Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. *J Pathol* 206(3): 356–365
- Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. *Ann Surg* 224(4): 463–473
- Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL (1985) Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. *Lancet* 1(8425): 366–368
- Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. *Eur J Cancer* 37(Suppl 4): S9–S15
- Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M (2002) Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. *Br J Surg* 89(12): 1525–1531
- Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* 19(13): 3159–3167
- Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2006) Phase II study of erlotinib in patients with advanced biliary cancer. *J Clin Oncol* 24(19): 3069–3074
- Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 355(24): 2542–2550
- Shaib YH, El Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. *Am J Gastroenterol* 102(5): 1016–1021
- Shiojiri N (1997) Development and differentiation of bile ducts in the mammalian liver. *Microsc Res Tech* 39(4): 328–335
- Shirabe K, Shimada M, Tsujita E, Aishima S, Maehara S, Tanaka S, Takenaka K, Maehara Y (2004) Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. *Am J Surg* 187(4): 538–542
- Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. *Hepatology* 41: 5–15
- Sobin LH, Wittekind CH (2002) *TNM Classification of Malignant Tumours*, 6th edn. New York: Wiley-Liss Inc
- Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. *J Gastrointest Surg* 4(6): 567–579
- Sprinzel MF, Schimanski CC, Moehler M, Schadmand Fischer S, Galle PR, Kanzler S (2006) Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. *BMC Cancer* 6: 190

- Strom BL, Hibberd PL, Soper KA, Stolley PD, Nelson WL (1985) International variations in epidemiology of cancers of the extrahepatic biliary tract. *Cancer Res* 45(10): 5165–5168
- Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. *Mol Cancer Res* 5(3): 203–220
- Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, Ota H, Yoshioka S, Kato H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Wakasa K, Monden M (2006) Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. *Oncol Rep* 15(3): 525–532
- Ukita Y, Kato M, Terada T (2002) Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence *in situ* hybridization, *in situ* hybridization, and immunohistochemistry. *J Hepatol* 36: 780–785
- Viloria Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies *in vivo*: a role for altered tumor angiogenesis. *Cancer Res* 61(13): 5090–5101
- Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. *N Engl J Med* 324(1): 1–8
- Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M (2004) Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. *J Gastrointest Surg* 8(4): 448–453
- Yamamoto M, Takasaki K, Yoshikawa T, Ueno K, Nakano M (1998) Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? *J Surg Oncol* 69(3): 162–167
- Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2(2): 127–137
- Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. *J Hepatol* 41(5): 808–814
- Zetter BR (1998) Angiogenesis and tumor metastasis. *Annu Rev Med* 49: 407–424

Characterisation and protein expression profiling of annexins in colorectal cancer

R Duncan¹, B Carpenter², LC Main¹, C Telfer² and GI Murray^{*,1}

¹Department of Pathology, University of Aberdeen, Aberdeen, UK; ²Auvation Ltd, Crombie Lodge, Aberdeen Science Park, Balgowrie Drive, Aberdeen, UK

The annexins are family of calcium-regulated phospholipid-binding proteins with diverse roles in cell biology. Individual annexins have been implicated in tumour development and progression, and in this investigation a range of annexins have been studied in colorectal cancer. Annexins A1, A2, A4 and A11 were identified by comparative proteomic analysis to be overexpressed in colorectal cancer. Annexins A1, A2, A4 and A11 were further studied by immunohistochemistry with a colorectal cancer tissue microarray containing primary and metastatic colorectal cancer and also normal colon. There was significant increase in expression in annexins A1 ($P=0.01$), A2 ($P<0.001$), A4 ($P<0.001$) and A11 ($P<0.001$) in primary tumours compared with normal colon. There was increasing expression of annexins A2 ($P=0.001$), A4 ($P=0.03$) and A11 ($P=0.006$) with increasing tumour stage. An annexin expression profile was identified by *k*-means cluster analysis, and the annexin profile was associated with tumour stage ($P=0.01$) and also patient survival. Patients in annexin cluster group 1 (low annexin expression) had a better survival (log rank = 5.33, $P=0.02$) than patients in cluster group 2 (high annexins A4 and A11 expression). In conclusion, this study has shown that individual annexins are present in colorectal cancer, specific annexins are overexpressed in colorectal cancer and the annexin expression profile is associated with survival.

British Journal of Cancer (2008) 98, 426–433. doi:10.1038/sj.bjc.6604128 www.bjcancer.com

Published online 11 December 2007

© 2008 Cancer Research UK

Keywords: annexin; immunohistochemistry; proteomics; prognosis; tissue microarray

The annexins are a multigene family of calcium-regulated phospholipid-binding proteins (Gerke and Moss, 2003; Gerke *et al*, 2005). The annexins are classified into five groups (A–E), and within each of these groups, individual annexins are identified numerically. Annexins in group A are human annexins, with group B referring to animal annexins without human orthologs, group C to fungi and moulds, group D to plants and group E to protists (Liemann and Huber, 1997; Rand, 2000; Hayes and Moss, 2004; Rescher and Gerke, 2004; Lim and Pervaiz, 2007). The characteristic annexin structural motif is a 70-amino-acid repeat, called the annexin repeat. Four annexin repeats packed into an α -helical disk are contained within the C-terminal polypeptide core (Gerke and Moss, 2003). While all annexins share this core region, the N-terminal varies widely between annexins, and it is this diversity of N-terminal amino-acid sequence that gives the individual annexins their functional differences and biological activities (Gerke and Moss, 2003; Gerke *et al*, 2005). There are 12 human annexin subfamilies (A1–A11 and A13) that have been found to have various intra- and extracellular roles in a range of cellular processes such as cell signalling, ion transport, cell division and apoptosis (Gerke and Moss, 2003; Gerke *et al*, 2005).

All annexins share an ability to bind to negatively charged phospholipid membranes in a calcium-dependent manner. This property is found within the annexin core motif where the calcium- and membrane-binding sites are located. Annexins bind to the cytosolic surface of the plasma membrane and to organelle membranes such as the Golgi apparatus. This binding can be reversed by the removal of calcium, freeing the annexin from the phospholipid membrane. However, the functional significance of their reversible membrane-binding ability remains unknown in many annexins, although in some it is thought to be important for vesicle aggregation and membrane organisation (Liemann and Huber, 1997; Rand, 2000; Rescher and Gerke, 2004; Lim and Pervaiz, 2007). Although all annexins share this binding property, there is variation in calcium sensitivity and phospholipid specificity between individual annexins. For example, within one cell there can be differences in the distribution of annexins, with annexin A1 having an endosomal localisation, A2 to be found in cytosol and A4 being associated with the plasma membrane (Liemann and Huber, 1997).

Some annexins are capable of calcium-independent binding and several have roles in vesicle aggregation. Annexins A1, A2 and A11 function in cooperation with other calcium-binding proteins to form complexes while annexins A1, A2 and A5 interact with cytoskeletal proteins. Many annexins are involved in exocytic and endocytic pathways and some have roles in ion channel regulation (Gerke and Moss, 2003). Extracellularly, annexin A1 has a role in controlling the inflammatory response while annexin A2 is present on the external surface of endothelial cells, where it may act as a receptor for ligands, including plasminogen and tissue plasminogen

*Correspondence: Professor GI Murray, Department of Pathology, University Medical Buildings, Foresterhill, Aberdeen AB25 2ZD, UK; E-mail: g.i.murray@abdn.ac.uk

Received 24 August 2007; revised 12 November 2007; accepted 15 November 2007; published online 11 December 2007

Current Status of Surgery for Pancreatic Cancer

Koichi Hirata^a Shinichi Egawa^b Yasutoshi Kimura^a Takayuki Nobuoka^a
Hidenori Oshima^a Tadashi Katsuramaki^a Toru Mizuguchi^a Tomohisa Furuhashi^a

^aDepartment of Gastrointestinal Surgery and Oncological Surgery, Sapporo Medical University School of Medicine, Sapporo, and ^bDepartment of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Tohoku, Japan

Key Words

Pancreatic cancer, incidence · Surgery, pancreatic cancer

Abstract

Background: In Japan the annual incidence of pancreatic cancer has increased over the last decade, but no advancement has been made in the long-term prognosis after resection. The significant differences in the surgical procedures between Western countries and Japan have been discussed. Therefore, an adequate comparison and analysis of the data from Japan, Europe and the USA is required. This review evaluates many important published reports from Japan which influence surgical procedure. **Methods:** Several important highlights and controversies regarding the concept of surgical treatment and surgical procedure are discussed comparing the results in Japan with those in Western countries. **Results:** No significant difference in diagnostic strategy using various imaging methods was observed between Japan and Europe. The stage classification for pancreatic cancer by the Japanese Pancreatic Society (JPS) seems to be superior to others, because the results on long-term prognosis after pancreatic resection of cases with pancreatic head cancer, diagnosed as tubular adenocarcinoma, has been arranged logically. Pancreatic resection with extended radical dissection is recommended in Japan, but several clinical studies from Europe and the USA suggest that this is ineffective. The basic concepts of this controversy have recently come closer altogether. Scientific

clinical trials for instance on the necessity of adjuvant treatment, etc., are now on-going. **Conclusion:** The characteristics on diagnosis and treatment of pancreatic cancer in Japan are described. The JPS registration system for pancreatic cancer can provide much more information, i.e. dependency on diagnostic methods, highly frequent sites of lymph node and of distant metastases, the prognosis of small pancreatic cancers, etc. The indication for any surgical treatments should be limited to cases with the possibility of cancer free margins.

Copyright © 2007 S. Karger AG, Basel

Introduction

Pancreatic cancer is the fifth leading cause of cancer death in Japan. The lethality of this malignant neoplasm is demonstrated by the annual incidence which is roughly more than 17,000 patients/year. Unfortunately, the incidence of pancreatic cancer is increasing in Japan and, aside from tobacco, its exact risk factors remain poorly understood. Pancreatic cancer registration has been carried out by the Japanese Pancreas Society (JPS) since 1981, and the 5-year survival on this registry after pancreatic resection is 13.1% [1]. According to the JPS classification, the 5-year survival in the cases with stage I, defined as no metastasis to regional lymph nodes and no neural invasion, is 61.0%, and those for stages II, III, IVa and IVb are arranged in a parallel manner. This might suggest the

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2007 S. Karger AG, Basel
0255-4886/07/0242-0137\$23.50/0

Accessible online at:
www.karger.com/dsu

Koichi Hirata
S-1, W-16, Chuo-ku
Sapporo 060-8543 (Japan)
Tel. +81 11 611 2111, ext. 3280, Fax +81 11 613 1678
E-Mail a.narita@sapmed.ac.jp

accuracy of the JPS stage classification and the effectiveness of the surgical procedure for carcinoma of the pancreas. However, the number of the patients with stage I is extremely low (about 1.4%/year) in spite of the development of imaging diagnoses, and most of the cases are still in stage IVa and IVb.

Surgical techniques in Japan have been standardized on a basic treatment concept for invasive pancreatic cancer, which aims for a safe pancreatectomy procedure and aggressive dissection with a negative surgical margin. The results from this concept were expected to show qualitatively better treatment results for advanced pancreatic cancer in Japan during the 1990s. However, a longer survival rate has not yet come about because it is still difficult to diagnose patients with earlier stages of pancreatic cancer even though the screening system should have enabled this. It is well recognized that, upon surgical treatment, pancreatic cancer very often occurs in the retropancreatic extension, has lymph node metastases and neural invasion upon surgical treatment. The Japanese concept in this field recommends extended radical pancreatectomy, but this does not ascertain a better result as opposed to our expectations. A few institutes have had higher 5-year survival results of more than 30% [2–4]. However, these results were not based on a prospective randomized study and include various stages. The similar result on long-term prognosis have been observed in Europe and the USA [5–7], although extreme lymph node dissection and neural plexus dissection have not been performed. The effectiveness of postoperative adjuvant chemotherapy has recently been reported in randomized control trials (RCTs) [8–10]. Also in Japan, several trials on surgical procedures and adjuvant treatment have been reported [11]. In this review, the current status of surgery for pancreatic cancer in Japan is discussed in accordance with the introduction of international and Japanese trends mainly concentrating on the highlights and the controversies.

Diagnosis and Assessment of Resectability

In a patient with confirmed or suspected pancreatic cancer, the first clinical step in management is to determine the resectability and to evaluate of the tumor staging. Most of the clinical features, such as marked and rapid weight loss, persistent back pain, ascites, supraclavicular lymphadenopathy and ascites, are known as risk factors which reflect one or some of distant metastases such as hepatic metastases, systemic lymph node metastases, major stenosis in large vein (portal or superior mes-

enteric vein), neural invasion and peritoneal dissemination. In most cases these pathophysiologies are generally detected by ultrasound sonography, contrast computed tomography (CT), multi-detected CT and MRI. The existence of these features often make a patient select a palliative method such as bypass operation. However, resection of the tumor should be performed whenever no contraindicating risk is found. Pancreatic tumors are considered resectable when CT shows an isolated pancreatic mass without contiguous organ invasion, vascular involvement, nodal metastases, liver metastases or ascites. However, poor preoperative assessment of resectability by CT scan is known in detecting lymph node metastases, scattered local extension and small hepatic metastases. Is helical CT or dynamic MRI better for diagnosis [12]? Following diagnosis of a resectable pancreatic carcinoma, reliable detection of lymph node status is most important with regard to a curable resection. However, it has been reported that the diagnostic accuracy of CT imaging of nodal metastases varies from 42 to 58%, sensitivity 19–37%, specificity 60–92%, positive predictive value 47–83%, and negative predictive value 34–67% [13–16]. According to recent studies on ultrasonographic diagnosis, endoluminal ultrasonography is highly sensitive to detect invasion of major vascular strictures [17, 18]. The effectiveness of endoluminal ultrasonography in the diagnosis of pancreatic cancer gave a sensitivity of 95%, and a specificity of 80%, and negative predictive value of 80% [17]. Kaneko et al. [18] reported similar results with a slightly higher sensitivity of 96.9%, specificity of 91.2% and overall accuracy of 93.9% in the diagnosis of portal invasion. On the other hand, CT analysis resulted in a sensitivity of 83.9%, specificity of 74.3% and overall accuracy of 78.9%. Involvement of the venous system exceeding half the circumference of the vessel on CT is very suggestive of invasion, but this is not so when less than half of the vessel is involved, and it is not adaptable in artery systems. Accordingly, an indicative factor in the diagnosis of local cancer extension has not been established. Direct macroscopic observation and laparoscopic diagnosis are indicated in patients with pancreatic tumors not isolated from the surrounding tissue and vessels.

Importance of Staging

In Japan more than 70% of the pancreatic tumors requiring surgical treatment are located in the head of the pancreas (table 1) [1]. Others are located in the body and/or tail of the pancreas. The possibility of better prognosis

Table 1. Tumor location in the pancreas [1]

	Location				Total
	head	body-tail	head and body/body and tail	whole	
Tumor size					
TS1 (<2 cm)	638	159	25	2	824
TS2 (2–4 cm)	2,929	598	240	20	3,787
TS3 (4–6 cm)	1,519	476	479	31	2,505
TS4 (>6 cm)	652	366	773	214	2,005
Unknown	346	122	134	54	656
Total	6,084	1,721	1,651	321	9,777
Operation					
Resected	4,913	1,254	921	135	7,223
Palliative	965	230	517	117	1,829
Others	206	237	213	69	725
Total	6,084	1,721	1,651	321	9,777

by operation is limited to resected cases with Ro operation and no lymph node metastasis. There are several classifications for pancreatic cancer and we would like to compare some representative classifications, i.e. the Japanese Pancreas Society (JPS) classification (table 2a) [1], the 2002 Union International contre la Cancer (UICC) tumor node metastasis (TNM) classification (table 2b) [19], and the American Joint Committee on Cancer (AJCC) (in cooperation with the TNM committee of the International Union Against Cancer) staging system. In their initial versions, there were wide differences in determining the rules on stage-for-stage comparison, but have become much closer together with the latest revisions (table 3). These systems may be contributive as predictive prognostic factors for overall survival, but they are sometimes not useful for planning treatment because patients with advanced stages of disease may not be candidates for surgical resection. This fact has remained the difficulty of staging based on the skill and efforts of surgeons of pancreatic cancer. Otherwise, highly qualified surgeons have given much effort to curability under the rules of the staging systems, but it is very difficult to definitely identify regional metastases and invasion at the macroscopic level in the perioperative period. Most of these cases unfortunately resulted in non-curable operations according to the pathological diagnosis, which contributes to the scientific support of clinical knowledge. Recent improvements in diagnostic systems before/after surgery may contribute somewhat to the prognosis and new treatment, i.e. mo-

lecular target therapy, etc., in near future. Pancreatic cancer is very malign with a high ability to metastasize to the lymph nodes and to invade vessels (lymph canals, arteries and veins) and the perineural region. Therefore, pathological descriptions for these areas should be made.

Much molecular research for the diagnosis of micro-metastases via the lymph system and via the blood stream are of clinical significance; some have proven the significant influence of micrometastases in the resected lymph nodes and/or cancer-positive conditions in the blood stream on survival (table 4) [21–30]. However, diagnostic methods using immunohistochemical or molecular analysis are not supported by medical insurance in Japan. Some molecular research concluded that the relationship between morphological and molecular diagnoses is very useful for prognosis, but each diagnostic value is proven as an independent factor on statistical analysis. In future the development of molecular diagnosis could contribute not only to the strategy for treatment but also to the decision of targeting treatment. At present, no meaningful treatment method, except surgery, has been invented, and a breakthrough, such as the appearance of molecular target drugs, is awaited.

Comparison between JPS and UICC Staging Classifications

Advancements in the treatment of pancreatic cancer in Japan have been supported by the National Pancreatic Cancer Registry of the JPS. The success of this registry has resulted in the provision of macroscopic and microscopic standard criteria, standard guidelines for the diagnosis, treatment, and introduction of risk factors on prognosis. Finally, the JPS classification was established on the basis of these data and it has been recognized that the stage classifications for pancreatic cancer reveal the more stratified and informative criteria. Many Japanese surgeons depend on these staging criteria to determine treatment strategy and obtain informed consent. By analyzing the JPS data on 3,979 patients who underwent resection for tubular adenocarcinoma of the pancreatic head, Isaji et al. [31] recently reported that the JPS classification is more reliable for predicting outcomes as compared with the UICC classification. In the past there have been wide discrepancies in the prognostic results for pancreatic cancer at each stage between Japan and the United States. This might be due to differences in clinical staging between the JPS and the UICC. In 1998, Kawarada et al. [32] compared the JPS 4th edition (1993) and the

Table 2. Stage groupings according to the JPS [1] (a) and UICC [19] (b) classifications

a JPS					b UICC				
	M0			M1			M0		M1
	N0	N1	N2	N3	N0		N0		
Tis	0					Tis	0		IV
T1	I	II	III			T1	IA		
T2	II	III	III			T2	IB	IIIB	
T3	II	III	IVa			T3	IIA	IIIB	
T4	IV					T4	III	III	

Wide differences with regard to the grouping are observed for tumor status and lymph node metastasis.

Table 3. Comparison of the definitions for T number in the latest publications between the JPS 5th edition (2002) [1] and the UICC 6th edition (2002) [19]

Classification	JPS 5th ed. (2002)	UICC 6th ed. (2002)
T1	Tumor limited to the pancreas, ≤2 cm in greatest dimension	Tumor limited to the pancreas, ≤2 cm in greatest dimension
T2	Tumor limited to the pancreas, >2 cm in greatest dimension	Tumor limited to the pancreas, >2 cm in greatest dimension
T3	Tumor that has extended into any of the following: bile duct (CH), duodenum (DU), peripancreatic tissue (S, RP)	Tumor extends beyond the pancreas but without involvement of celiac axis or superior mesenteric artery
T4	Tumor that has extended into any of the following: adjacent large vessels (PV, A), extrapancreatic nerve plexus (PL), other organs (OO)	Tumor involves celiac axis or superior mesenteric artery

Table 4. Detection of disseminated pancreatic cancer cells in the peripheral blood samples from Japanese reports

Markers	Samples	Positive/total patients (detection rates, %)	References
K-ras mutation (codon 12)	Peripheral blood	2/6 (33.3%)	Tada et al. [21], 1993
K-ras mutation (codon 12)	Liver	13/17 (76.5%)	Inoue et al. [22], 1995
K-ras mutation (codon 12)	Peripheral blood	10/10 (100%)	Nomoto et al. [23], 1996
K-ras mutation (codon 12)	Lymph nodes	4/6 (66.6%)	Tamagawa et al. [24], 1997
K-ras mutation (codon 12)	Lymph nodes	8/13 (61.5%)	Ando et al. [25], 1997
CEA mRNA	Peripheral blood	3/9 (33.3%)	Funaki [26], 1998
Keratin 19 mRNA (stage IV)	Peripheral blood	2/19 (10.5%)	Aihara et al. [27], 1997
	Portal blood	1/18 (5.6%)	
CEA mRNA	Peripheral blood	13/21 (61.9%)	Miyazono et al. [28], 1999
Chymotrypsinogen mRNA	Peripheral blood	7/10 (70%)	Kuroki et al. [29], 1999
α4GnT mRNA (stage IV)	Peripheral blood	33/43 (76.7%)	Ishizone et al. [30], 2006

UICC 5th edition (1997), and the results showed that the JPS system was more reliable for long-term prognosis. However, the opinion leaders in the Western countries suggested that the rule of classification of the JPS 4th edition was very complicated and not useful clinically. Japa-

nese researchers surely also have a similar impression. Since then, further efforts by the JPS Review Committee of the General Rules on the Study of Pancreatic Cancer have been asked to establish more a simple and reliable staging classification. Finally, the JPS published the 6th




Fig. 1. a Survival curves according to the JPS staging of the patients who underwent resection for tubular adenocarcinoma of the pancreas head. Altogether the survival rates of the five stages differed significantly. **b** Survival curves according to the UICC stages. No difference could be found between stages Ib and IIa, and stages IIb, III and IV [19].

Japanese edition in 2002 and the 2nd English edition in 2003. On the other hand, the 6th edition of UICC was published in 2002, which showed even wider differences in staging from that of the JPS (table 3). Therefore, the first purpose of Isaji et al. [31] was to analyze the results of operative treatment over the last 15 years (18,629 cases) to determine whether the prognosis of pancreatic cancer had improved, and secondly to compare the usefulness of the two classifications on outcome. Generally, it is understood that it is difficult to decide the best research method for such a comparison. Therefore, they focused on the reliability of predicting outcome for 3,979 resected cases with tubular adenocarcinoma localized in the head of

pancreas. The results were as follows: (1) the survival rate was correlated with the Japanese stage classification (fig. 1a); (2) the extent of the primary tumor (T category) indicates the significant difference in the survival rates among the 4 groups in both classifications; (3) the extent of lymph node involvement and of extrahepatic tissue invasion better reflects prognosis by the JPS rules than the UICC rules, and (4) the UICC staging system does not reflect differences in prognosis among the stages, especially between stages Ib and IIa, and stages IIb, III and IV (fig. 1b).

These results indicate that the JPS classification may offer a better prediction of prognosis.

Surgical Treatment

Surgical treatment of pancreatic cancer unfortunately has only a low success rate with regard to its long-term prognosis, and there is only a likelihood of cure following operation [33]. Recent studies in Japan and also in Western countries show that pancreaticoduodenectomy is associated with a 5-year survival of 10–20% [1], which has remained unchanged over the last 10 years. The surgical mortality rate of less than a few percent has improved. The most important prognostic factor for long-term survival after radical resections has been shown to be nodal status. In general, the 5-year survival after pancreaticoduodenectomy is roughly 10% for node-positive disease, while it can be 25–30% for node-negative disease. However, it is impossible to definitely detect the positive lymph nodes before and/or during surgery. Therefore, patients without the contraindications for curative resection, i.e. the presence of distant metastases, peritoneal seeding, tumor infiltration to the celiac artery or superior mesenteric artery extension of tumor tissue into the mesentery, etc., should receive the appropriate radical operation to improve their outcome.

Most hospitals in Japan have experience with extensive radical resection including excision of the portal vein, total or extensive regional pancreatectomy and extensive retroperitoneal lymphadenectomy. Some have suggested the effectiveness of extensive radical resection [2, 3]. However, no evidence from RCTs has been reported.

Current Concept in Japan

In 2004, Matsuno et al. [34] reported the results of 20 years experience with the pancreatic cancer registry in Japan. The total number of cases was 23,302, of which the number of epithelial and non-epithelial tumors were 11,819 and 0, respectively, and the number of the cases without histological diagnosis was 11,483. Data analysis was performed using SPSS software.

The male to female ratio was 1.58:1.00. The overall resectability rate was approximately 40% for the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas. The 5-year survival in the invasive carcinoma group was 9.7%, and wide differences were observed between the various histologies of the resected cases ranging from 10.7 to 44.8% as follows: tubular adenocarcinoma 10.7% (well differentiated type 13.1%, moderately differentiated type 9.3%, poorly differentiated type 9.3%); papillary adenocarcinoma 26.1%; adenosquamous carcinoma 15.8%, etc. Comparing the 5-year survival limited to cases with tubular adenocarcinoma,




Fig. 2. Cumulative survival rates in relation to lymph node dissection in all patients (**a**; log rank test, $p = 0.10$ for D_0 , D_1 , and D_2), patients with stage I and stage II cancer (**b**; $p = 0.95$), and patients with stage III cancer (**c**; $p = 0.81$) [36]. There were no significant differences. D_0 = No lymph node dissection; D_1 = N_1 lymph node dissection; D_2 = N_2 lymph node dissection.

no differences have been observed over the past 20 years. Namely, no improvement in outcome has been observed after surgical treatment. On the other hand, in extensive radical pancreatectomies performed from 1991 to 2000 as the standard operation for pancreas cancer, the higher resectability was found to be more than 40%, in relation to the result of about 25% seen around 1980. But no significant improvement in survival rate has been seen.

Nakasako et al. [35] reported their experience with the extensive radical operation at one institute (186 cases) and no difference in 5-year survival was found: 7% during 1968–1979, and 8% during 1978–1995. Hirata et al. [36] and Mukaiya et al. [37] tried to analyze cases collected from multi-institutional experience. The effectiveness of extensive radical pancreatectomies was poor (fig. 2). On

Table 5. Number of cases with invasive ductal pancreatic carcinoma [1]

Stage	Location				Total
	head	body-tail	head and body/ body and tail	whole	
I	87	46	3	0	136
II	126	41	26	7	200
III	938	137	28	9	1,112
IVa	1,507	370	140	19	2,036
IVb	2,407	781	1,112	210	4,570
Unknown	1,019	346	342	76	1,753
Total	6,084	1,721	1,651	321	9,777

the other hand, Ishikawa et al. [2] and Nagakawa et al. [3] reported better results with the extended radical operation, and also Hiraoka et al. [38] showed the effectiveness of combination therapy with the intraoperative radiation added to the extended radical operation.

The 5-year survival of the stage I cases with pancreas head carcinoma was 56.7%, and that for cancer of the pancreas body and tail was 58.5%.

The high-quality prognosis in stage I suggested that the diagnosis of such small cancers should be required to in order to obtain better results in pancreatic cancer. However, the proportion of tumor size 1 cases and stage I cases among all cases were very low: 8.4% (table 1) and 1.4%, respectively (table 5).

The absolute number and proportion of small pancreatic cancers have gradually been increasing year by year, but advances in treatment methods have not kept pace. Therefore, most Japanese surgeons still often face extremely advanced cases of pancreatic cancer.

Based on expert opinion, the concept of the surgery was synchronous resection of the artery or portal vein, wide dissection of the plexus nerve and extended dissection of lymph nodes. This concept has recently been changed due to the data from the JPS registration system.

Extensive Radical Pancreatectomy versus Standard Pancreatectomy

Due to the extremely high incidence of histological non-curative results with standard dissection, extended radical dissection is used in pancreatectomy to prevent the frequent local recurrence which tends to occur in spite of a clinically curative operation. Extended radical dissection, which has major complications such as severe diarrhea, uncomfortable intestinal condition due to dissec-

tion of the plexus nerve, malnutrition and lower quality of life, continued to be of interest compared with the standard operation during the 1990s in Japan. Several Japanese reports on extensive dissection suggested the benefit of clearance of lymph nodes and retroperitoneal connective tissue [2, 3], which might have somewhat influenced this field in other countries. However, no significant difference between extensive radical and standard pancreatectomy was suggested by multicenter prospective randomized trials [39, 40] in Western countries, and the reason for this difference was not scientifically clear among Japanese surgeons. A difference in the background of the patients undergoing surgical treatment has been suggested. Western institutes with a record of relatively good prognosis have introduced low resectability, but most Japanese institutes with high resectability have not experienced an advance in post-surgical prognosis. For example, the highly advanced cases might be included more often in Japan than in Western countries. One retrospective study tried to address this issue [37], and indicated no survival advantage of extended dissection, except for a limited group of patients with a small number of microscopic lymph node metastases. No significant difference between extended and standard operations was found in an RCT study by Yeo et al. [39] in the USA and Pedrazzoli et al. [40] in Italy. The patients who received either the extended or standard operation had high rates of local recurrence and hepatic metastases, and they died. This poor prognosis may be due to the poor condition of the patients at operation who already had systemic disease. Nagino and Nimura [41] recently reported no statistical difference between the extended radical and standard operations for patients with stage II, III and IVa pancreatic cancer among Japanese patients by RCT. The result showed that the 1- and 3-year survival rates were 76.5 and 29.3% for the standard procedure, and 53.8 and 15.1% for the extended procedure. A slightly worse prognosis was suggested for the extended operation.

Accordingly, there is doubt about the significance of extensive dissection not only for advanced stages but also for earlier stages of pancreatic cancer.

In the near future, patients with or without indications for surgical treatment may be selected preoperatively according to the biological behavior of the cancer cells.

Indication of Vascular Resection

Nakao et al. [42] recommended extended radical resection for elective patients and concluded that the most important indication of this procedure is to obtain surgical cancer-free margins. There is no indication that the

Table 6. Portal and/or superior mesenteric vein resection in pancreatic cancer in Japan

References	Patients	nPVR	Type of procedure	Year
Mimura et al. [44]	71	55	PD:28, TP:27	1994
Takahashi et al. [45]	137	79	PD:42, TP:32	1994, 1995
Nakao et al. [46]	200	146	TP:69, PD:57, DP:9, PPPD:11	1995, 2001
Imaizumi et al. [47]	480	172	Extend PD:150, Extend TP:22	1998
Ishikawa et al. [48]	43	27	PD:27	1998
Naganuma et al. [49]	83	30	PD, TP, DP, PPPD	1998
Shibata et al. [50]	74	28	PD:23, TP:3, DP:2	2001
Kawada et al. [51]	66	28	PD:20, TP:5, PPPD:3	2002
Aramaki et al. [52]	69	22	PD:14, TP:7, DP:1	2003
Nakagohri et al. [53]	81	33	PD, DP	2003

nPVR = Number of patients who underwent synchronous portal vein resection; PD = pancreatoduodenectomy; TP = total pancreatectomy; DP = distal pancreatectomy; PPPD = pylorus-preserving pancreaticoduodenectomy.

surgical margins will become cancer positive if extended resection is used in these patients.

Because of the absence of any RCT, Siriwardana and Siriwardana [43] made a detailed systematic review of outcome in patients following superior mesenteric vein (SMV) and/or portal vein (PV) resection during pancreatectomy. Japanese studies are shown in tables 6 and 7 [44–53]. Although regional pancreatectomy was recommended by Fortner [54] in 1974, this procedure is unfortunately associated with extremely high morbidity and no improvement in prognosis. Therefore, tumor extension to SMV/PV, superior mesenteric or celiac artery was recognized as a contraindication to surgical resection.

In 1996, Fuhrman et al. [55] reported no difference in hospital stay, morbidity, mortality, tumor size, margin positivity, modal positivity or tumor DNA content between two groups without or with SMV/PV resection. This study suggested that the development of SMV/PV resection was not significant and also that there is an inherent biological difference. However, when the purpose is to obtain cancer-free margins by PV/SMV resection, most Japanese surgeons would be eager to resect them simply for the low possibility of a good prognosis. Among those patients with systemic disease, only a few could be supported by adjuvant chemotherapy.

Effectiveness of Surgical Treatment for Advanced Pancreatic Cancer of the Pancreas

It has been discussed whether highly advanced but locally resectable pancreatic cancer can be adapted to surgical treatment or not. Imamura and Doi [56] faced this

Table 7. Morbidity, mortality and pathohistological results after portal and/or superior mesenteric vein resection in pancreatic cancer in Japan

References	nPVR	Morbidity, %	Mortality, %	PV(+) %	RM(+) %
Mimura et al. [44]	55		11		43.6
Takahashi et al. [44]	79		9.5	61	38
Nakao et al. [46]	146		5.5	71	58.2
Imaizumi et al. [47]	172	23	5	60.4	
Ishikawa et al. [48]	27			85.1	
Naganuma et al. [49]	30	16	1.2		36.6
Shibata et al. [50]	28	32	4	58.3	29
Kawada et al. [51]	28	46	4	75	64
Aramaki et al. [52]	22	9	4.5	63.4	
Nakagohri et al. [53]	33		6.1	51.5	24.2

PV(+) = Percentage of patients with portal vein involvement in surgical specimen; RM(+) = percentage of patients with resection margin-positive.

problem in a multicenter RCT comparing surgical resection and radiochemotherapy for locally advanced pancreatic cancer (limited strictly only to cases with JPS stage IVa). This study was performed using strict selection criteria, the final decision being made by direct observation and judgment during laparotomy after the preoperative diagnosis of stage IVa. It was concluded that such cancers, without involvement of the common hepatic artery or superior mesenteric artery, can be successfully treated by experienced surgeons at specialized centers, so-called

high-volume centers. Therefore, a substantial number of patients with stage IVa cancer still have curatively resectable disease and could have a more favorable outcome with surgery. Most skillful surgeons continue to resect stage IV tumors today.

No-Touch Isolation Technique

In order to prevent blood stream metastasis, the concept of isolated pancreatectomy [57] was created. With this aggressive procedure the patient undergoes bypass catheterization of the portal vein to decompress the congestion and prevent the shedding of cancer cells induced by the surgical manipulations of the pancreas head. Japanese reports on the incidence of pancreatic cancer cells in peripheral blood, bone marrow and liver tissue (table 4) have shown that this is the cause of distant metastases, which is supported by immunohistochemistry and molecular biological studies. Research has suggested the meaningful relationship between positive cancer cells in peripheral blood and distant metastases in cancer.

Kobayashi et al. [58] and Nakao and Takagi [57] suggested that the non-touch isolation technique (NTIT) could prevent liver metastases. During NTIT, isolation of the portal vein precedes ligation of the surrounding veins after dividing the duodenum and pancreas. Hirota et al. [59] proposed a different method of NTIT: ligation of Henle's gastrocolic trunk vein at the communicating point to the superior mesenteric vein, then division of the stomach or the upper duodenum, pancreas, choledochus, and jejunum. The pancreatic duct and choledochal duct should be ligated to prevent dissemination. Thereafter, the ligation of the portal vein branches follows. It is characteristic that no Kocherization is performed until all vascular branches are completed and no catheterization to the portal vein is needed. A comparative study of the NTIT and the conventional procedure with extensive intraoperative peritoneal lavage revealed: (1) the rate of molecular detection determines the rate of cancer cells in the portal venous blood and in the lymphatic fluid, and (2) the different frequency of hepatic metastasis, local recurrence and peritoneal dissemination. Further comparative study is necessary to confirm the significance of the NTIT procedure in pancreatic cancer surgery.

Mortality after Pancreatic Resection

Pancreatic resection is a high-risk surgical procedure with considerable postoperative morbidity and mortality. The hospital mortality rate after pancreatic resection has decreased during last 15 years, but there is a very wide variation in rates between institutes and countries. Re-

ports on the relationship between hospital volume and mortality after pancreatic resection provide a convincing evidence of an need for centralization, as several studies have assessed the impact of referral to high-volume centers on morbidity and mortality after pancreaticoduodenectomy [60–62]. Mortality rates at the high-volume centers are less than 5% and most reported less than 2%. Otherwise, centers with less experience continue to report mortality rates ranging from 7 to 15%. Birkmeyer et al. [61] reported the adjusted in-hospital mortality (1994–1999) among Medicare patients undergoing pancreatic resections: 16.3% (1 case/year), 14.6% (1–2 cases/year), 11.0% (3–5 cases/year), 7.2% (6–16 cases/year) and 3.8% (>16 cases/year). Therefore, Birkmeyer et al. [61] analyzed the summarized surgeon-specific and institute-volume outcome. Surgeon volume was divided into 3 groups: low (<2 cases/year); middle (2–4 cases/year), and high (>4 cases/year). Institute volume was divided into 3 groups: low (<3 cases/year); middle (3–13 cases/year), and high (>13 cases/year). Low-volume surgeons could have better results at higher-volume institutes. Further study is expected to clarify the influence of pancreatic condition on morbidity, i.e. parenchymal fibrosis and main pancreatic duct size and coexistent disease.

In some European countries such as the United Kingdom and Germany, centralization of institutes with a system of high-risk surgical procedures has been recommended, but its effects have not yet been analyzed and no precise report has been made [63]. It seems that the overall results are not changed. The data on hospital volume and mortality after pancreatic resection are too heterogeneous to perform a meta-analysis, but a systematic review shows convincing evidence of an inverse relation between hospital volume and mortality, and enforces the plea for centralization [64]. In Japan, there is no national registry concerning the outcomes of surgical treatment but the Japanese health insurance system is undergoing objective change which may lead to centralized systems. Cases will be optimized and medical costs minimized when patients with pancreatic cancer are referred to high-volume institutes.

Acknowledgements

We thank Ms. Akane Narita for the preparation of this paper and also Prof. Norio Kaminishi for recommending this presentation to the journal.

References

- 1 Pancreatic Cancer Registration Committee in Japan Pancreas Society. Pancreatic cancer registration of JPS: the summary for 20 years (in Japanese). *J Jpn Pancreas Soc* 2003;18: 101-169.
- ▶2 Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T: Practical usefulness of lymphatic and connective tissue clearance for carcinoma of the pancreas head. *Ann Surg* 1988;208:215-220.
- ▶3 Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, Ueno K, Miyazaki I: Results of extensive surgery for pancreatic carcinoma. *Cancer* 1996;77:640-645.
- ▶4 Takahashi S, Ogata Y, Miyazaki H, Maeda D, Murai S, Yamataka K, Tsuzuki T: Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. *World J Surg* 1995;19:653-659.
- ▶5 Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. *Ann Surg* 1995;221:59-66.
- ▶6 Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database. *J Am Coll Surg* 1999;189: 1-7.
- ▶7 Trede M, Schwall J, Cameron J: Improved hospital morbidity, mortality and survival after the Whipple procedure. *Ann Surg* 1987; 206:358-365.
- ▶8 Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004; 350:1200-1210.
- ▶9 Kim HJ, Czischke K, Brennan MF, Conlon KC: Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? *J Gastrointest Surg* 2002;6:763-769.
- ▶10 Klinkenbijl JH, Jeekel J, Sahnoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennisman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. *Ann Surg* 1999;230:776-784.
- ▶11 Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. *Cancer* 2002; 95:1685-1695.
- ▶12 Ichikawa T, Haradome H, Hachiya J, Nitori T, Ohtomo K, Kinoshita T, Araki T: Pancreatic ductal adenocarcinoma preoperative assessment with helical CT versus dynamic MR imaging. *Radiology* 1997;202:655-662.
- ▶13 Oshikawa O, Tanaka S, Ioka T, Nakaizumi A, Hamada Y, Mitani T: Dynamic sonography of pancreatic tumors: comparison with dynamic CT. *AJR Am J Roentgenol* 2002;178: 1133-1137.
- ▶14 Saisho H, Yamaguchi T: Diagnostic imaging for pancreatic cancer, computed tomography, magnetic resonance imaging, and positron emission tomography. *Pancreas* 2004; 28:273-278.
- ▶15 Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr: MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and respectability using a multiphasic technique with curved planner reformations. *AJR Am J Roentgenol* 2004;182:419-425.
- ▶16 Scaglione M, Pinto A, Romano S, Scialpi M, Volterrani L, Rotondo A, Romano L: Using multidetector row computed tomography to diagnose and stage pancreatic carcinoma: the problems and the possibilities. *JOP* 2005; 13;6:1-5.
- ▶17 Glasbrenner B, Schwarz M, Pauls S, Preclik G, Beger HG, Adler G: Prospective comparison of endoscopic ultrasound and endoscopic retrograde cholangiopancreatography in the preoperative assessment of masses in the pancreatic head. *Dig Surg* 2000;17:468-474.
- ▶18 Kaneko T, Nakao A, Inoue S, Harada A, Nonami T, Itoh S, Endo T, Takagi H: Intra-portal endovascular ultrasonography in the diagnosis of portal vein invasion by pancreaticobiliary carcinoma. *Ann Surg* 1995;222: 711-718.
- ▶19 Sobin LH, Wittekind C (eds): International Union Against Cancer. TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002.
- ▶20 Wray CJ, Ahmad SA, Matthews JB, Lowy AM: Surgery for pancreatic cancer: Recent controversies and current practice. *Gastroenterology* 2005;128:1626-1641.
- ▶21 Tada M, Omata M, Kawai S, Saisho H, Ohta M, Saiki RK, Sninsky JJ: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. *Cancer Res* 1993;53:2472-2474.
- ▶22 Inoue S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H: Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) analysis. *Jpn J Cancer Res* 1995;86:626-630.
- ▶23 Nomoto S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H: Detection of ras gene mutations in peripheral blood with pancreatic adenocarcinoma. *Jpn J Cancer Res* 1996; 87:793-797.
- ▶24 Tamagawa E, Ueda M, Takahashi S, Sugano K, Uematsu S, Mukai M, Ogata Y, Kitajima M: Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma. *Clin Cancer Res* 1997;3:2143-2149.
- ▶25 Ando N, Nakao A, Nomoto S, Takeda S, Kaneko T, Kurokawa T, Nonami T, Takagi H: Detection of mutant K-ras in dissected para-aortic lymph nodes of patients with pancreatic adenocarcinoma. *Pancreas* 1997;15:374-378.
- ▶26 Funaki NO, Tanaka J, Hosotani R, Kogire M, Suwa H, Imamura M: Quantitative analysis of carcinoembryonic antigen messenger RNA in peripheral venous blood and portal blood of patients with pancreatic ductal adenocarcinoma. *Clin Cancer Res* 1998;4:855-860.
- ▶27 Aihara T, Noguchi S, Ishikawa O, Furukawa H, Hiratsuka M, Ohigashi H, Nakamori S, Monden M, Imaoka S: Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. *Int J Cancer* 1997;72: 408-411.
- ▶28 Miyazono F, Takao S, Natsugoe S, Uchikura K, Kijima F, Aridome K, Shinchi H, Aikou T: Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. *Am J Surg* 1999;177:475-479.
- ▶29 Kuroki T, Tomioka T, Tajima Y, Inoue K, Ike-matsu Y, Ichinose K, Furui J, Kanematsu T: Detection of the pancreas-specific gene in the peripheral blood of patients with pancreatic carcinoma. *Br J Cancer* 1999;81:350-353.
- ▶30 Ishizone S, Yamauchi K, Kawa S, Suzuki T, Shimizu F, Harada O, Sugiyama A, Miyagawa S, Fukuda M, Nakayama J: Clinical utility of quantitative RT-PCR targeted to alpha 1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. *Cancer Sci* 2006;97:119-126.
- ▶31 Isaji S, Kawarada Y, Uemoto S: Classification of pancreatic cancer: comparison of Japanese and UICC classifications. *Pancreas* 2004;28:231-234.
- ▶32 Kawarada Y, Das BC, Naganuma T, Isaji S: Surgical treatment of pancreatic cancer. Does extended lymphadenectomy provide a better outcome? *J Hepatobiliary Pancreat Surg* 2001;8:224-229.
- ▶33 Smeenk HG, Tran TCK, Erdmann J, Eijck CHJ, Jeekel J: Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? *Langenbecks Arch Surg* 2005;390:94-103.

- ▶ 34 Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. *Pancreas* 2004;28:219-230.
- 35 Nakasako Y, Hanyu F, Takasaki K: Indications for extended radical and pylorus-preserving Whipple operation for pancreatic cancer; in Hanyu F, Takasaki K (eds): *Pancreatoduodenectomy*. Berlin, Springer, 1997, pp 99-106.
- ▶ 36 Hirata K, Sato T, Mukaiya M, Yamashiro K, Kimura M, Sasaki K, Denno R: Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. *Arch Surg* 1997;132:771-777.
- ▶ 37 Mukaiya M, Hirata K, Satoh T, Kimura M, Yamashiro K, Ura H, Oikawa I, Denno R: Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. *World J Surg* 1998;22:248-252.
- 38 Hiraoka T, Kanematsu K: Combined treatment of resection with intraoperative radiotherapy. Part 6: Tumors of the exocrine tissue: pancreatic cancer; in Beger HG, Warshaw AL, Buhler MW, Carr-Locke DL, Neoptolemos JP, Rusell C, Sarr MG (eds): *The Pancreas*. Oxford, Blackwell Science, 1998, pp 1085-1091.
- ▶ 39 Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. 2. Randomized control trial evaluating survival, morbidity, and mortality. *Ann Surg* 2002;236:355-368.
- ▶ 40 Pedrazzoli P, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. *Ann Surg* 1998;228:508-517.
- 41 Nagino M, Nimura Y: Does 'extended' surgery for pancreatic head adenocarcinoma have survival impact? (in Japanese). *J Jpn Surg Soc* 2006;107:173-176
- ▶ 42 Nakao A, Takeda S, Sakai M, Kaneko T, Inoue S, Sugimoto H, Kanazumi N: Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection. *Pancreas* 2004;28:289-292.
- ▶ 43 Siriwardana HP, Siriwardana AK: Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatotomy for cancer. *Br J Surg* 2006;93:662-673.
- ▶ 44 Mimura H, Mori M, Hamazaki K, Tsuge H: Isolated pancreatotomy for ductal carcinoma of the head of the pancreas. *Hepatogastroenterology* 1994;41:483-488.
- ▶ 45 Takahashi S, Ogata Y, Miyazaki H, Maeda D, Mural S, Yamataka K, Tsuzuki T: Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. *World J Surg* 1995;19:653-660.
- ▶ 46 Nakao A, Kaneko T, Takeda S, Inoue S, Harada A, Nomoto S, Ekmel T, Yamashita K, Hatsuno T: The role of extended radical operation for pancreatic cancer. *Hepatogastroenterology* 2001;48:949-952.
- ▶ 47 Imaizumi T, Hanyu F, Harada N, Hatori T, Fukuda A: Extended radical Whipple resection for cancer of the pancreatic head: operative procedure and results. *Dig Surg* 1998;15:299-307.
- ▶ 48 Ishikawa O, Ohigashi H, Sasaki Y, Nakano H, Furukawa H, Imaoka S, Takenaka A, Kasugai T, Ishiguro S: Intraoperative cytodiagnosis for detecting a minute invasion of the portal vein during pancreatoduodenectomy for adenocarcinoma of the pancreatic head. *Am J Surg* 1998;175:477-481.
- ▶ 49 Naganuma T, Isaji S, Kawarada Y: Staging and extended resection for pancreatic cancer. *Pancreas* 1998;16:355-362.
- ▶ 50 Shibata C, Kobari M, Tsuchiya T, Arai K, Anzai R, Takahashi M, Uzuki M, Sawai T, Yamazaki T: Pancreatotomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. *World J Surg* 2001;25:1002-1005.
- ▶ 51 Kawada M, Kondo S, Okushiba S, Morikawa T, Katoh H: Reevaluation of the indications for radical pancreatotomy to contraindication? *Surg Today* 2002;32:598-601.
- ▶ 52 Aramaki M, Matsumoto T, Etoh T, Ishio T, Himeno Y, Sasaki A, Yada K, Kawano K, Kitano S: Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma. *Hepatogastroenterology* 2003;50:263-266.
- ▶ 53 Nakagohri T, Kinoshita T, Konishi M, Inoue K, Takahashi S: Survival benefits of portal vein resection for pancreatic cancer. *Am J Surg* 2003;186:149-153.
- ▶ 54 Fortner JG: Regional resection of cancer of the pancreas: a new surgical approach. *Surgery* 1973;73:307-320.
- ▶ 55 Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB: Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. *Pancreatic Tumor Study Group. Ann Surg* 1996;223:154-162.
- ▶ 56 Imamura M, Doi R: Treatment of locally advanced pancreatic cancer: should we resect when resectable? *Pancreas* 2004;28:293-295.
- ▶ 57 Nakao A, Takagi H: Isolated pancreatotomy for pancreatic head carcinoma using catheter bypass of the portal vein. *Hepatogastroenterology* 1993;40:426-429.
- ▶ 58 Kobayashi S, Asano T, Ochiai T: A proposal of no-touch isolation technique in pancreatoduodenectomy for periampullary carcinomas. *Hepatogastroenterology* 2001;48:372-374.
- 59 Hirota M, Shimada S, Yamamoto K, Tanaka E, Sugita H, Egami H, Ogawa M: Pancreatotomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: a pilot study. *J Pancreat* 2005;6:143-151.
- ▶ 60 Birkmeyer JD, Siewers AE, Finlayson EVA, Stukel TA, Lucas FL, Batista I, Welch G, Wennberg DE: Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;346:1128-1137.
- ▶ 61 Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL: Surgeon volume and operative mortality in the United States. *N Engl J Med* 2003;349:2117-2127.
- ▶ 62 Gouma DJ, van Greenen RCI, van Gulik TM, de Haan RJ, de Wit LT, Busch ORC, Obertop H: Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. *Ann Surg* 2000;232:786-795.
- ▶ 63 Rosemurgy AS, Bloomston M, Serafini FM, Coon B, Murr M, Carey LC: Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. *J Gastrointest Surg* 2001;5:21-26.
- ▶ 64 Van Heek NT, Kuhlmann KFD, Scholten RJ, de Castro SM, Busch OR, van Gulik TM, Obertop H, Gouma DJ: Hospital volume and mortality after pancreatic resection. A systematic review and an evaluation of intervention in the Netherlands. *Ann Surg* 2005;242:781-790.

Acinar Cell Carcinoma of the Pancreas

Clinical Analysis of 115 Patients From Pancreatic Cancer Registry of Japan Pancreas Society

Hidehiko Kitagami, MD, PhD,* Satoshi Kondo, MD, PhD,* Satoshi Hirano, MD, PhD,* Hiroshi Kawakami, MD, PhD,† Shinichi Egawa, MD, PhD,‡§ and Masao Tanaka, MD, PhD¶||

Objectives: Acinar cell carcinoma (ACC) of the pancreas is a rare tumor, and many aspects remain unclear because no large-scale clinical studies have been conducted.

Methods: The present study investigated the clinical characteristics, treatment, and therapeutic outcomes of 115 patients registered in the Pancreatic Cancer Registry of the Japan Pancreas Society, and therapeutic plans were reviewed.

Results: Although ACC has been associated with advanced stage and poor prognosis, this tumor was resectable in 76.5% of the patients, and the 5-year survival rate after resection was favorable, being 43.9%.

Conclusions: Confirming the diagnosis of ACC preoperatively is difficult, but this diagnosis should be kept in mind while planning surgery for ordinary pancreatic cancer. Once the diagnosis has been confirmed, a possibility of surgical resection should be pursued to achieve better prognosis. If ACC is unresectable or recurrent, chemotherapy is likely to prove useful. Multidisciplinary therapy centering on the role of surgery will need to be established.

Key Words: acinar cell carcinoma

(*Pancreas* 2007;35:42–46)

Acinar cell carcinoma (ACC) is a relatively rare tumor of the pancreas compared with ductal cell carcinoma (DCC) and arises from acinar cells. Acinar cell carcinoma is a well-known entity, owing to its rarity, but for the same reason, a single institution is highly unlikely to treat many patients with ACC, and many issues concerning this tumor remain unclear. In particular, no consensus has been reached on surgical treatment or therapeutic outcomes.

Received for publication December 4, 2006; accepted February 14, 2007.
From the Departments of *Surgical Oncology and †Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo; ‡Japan Pancreas Society, Tokyo; §Department of Gastroenterological Surgery, Graduate School of Medicine, Tohoku University, Sendai; and ||Department of Surgery and Oncology, Graduate School of Medicine Science, Kyushu University, Fukuoka, Japan.
Reprints: Hidehiko Kitagami, MD, PhD, Department of Surgery, Kitami Red Cross Hospital, Kita 6, Higashi 2, Kitami City, Hokkaido 090-8666, Japan (e-mail: kitagami@phoenix-c.or.jp).
Copyright © 2007 by Lippincott Williams & Wilkins

The present study analyzed 115 patients with ACC accumulated in the Pancreatic Cancer Registry of the Japan Pancreas Society (JPS) for clinical characteristics, treatment, and therapeutic outcomes with reference to the literature.

MATERIALS AND METHODS

During a period of 23 years from 1981 through 2004, a total of 115 patients with ACC or adenoma were registered in the Pancreatic Cancer Registry of the JPS. On average, approximately 7 to 8 patients were registered annually (Fig. 1). From 1981 to 1999, both adenoma and adenocarcinoma were registered as adenocarcinoma, and so far, only one 60-year-old man in 2003 has been diagnosed with pancreatic acinar cell adenoma. The 115 patients (77 men and 38 women) displayed a mean age of 59.6 years (range, 30–85 years). Of the 115 patients, 112 patients were observed. Of the 112 patients, tumor was resected in 87 patients, and tumor stage was recorded for 74 patients. Among these patients, tumor stage, tumor markers, treatment, and therapeutic outcomes were investigated. Tumor staging including T, N, and M categories was based on the JPS staging system.¹ Survival was calculated using the Kaplan-Meier method, and a log-rank test was used to compare survival based on resection and stage.

RESULTS

Tumor Stage

The breakdown of tumor stages was as follows: stage I, n = 2; stage II, n = 15; stage III, n = 12; stage IVa, n = 21; stage IVb, n = 39; and unknown, n = 26 (Table 1). The annual number of the registration in relation to stage did not have the unevenness. According to JPS T classification system, T4 accounted for 55.3% of the total, and positive portal vein invasion (PV), arterial invasion (A), and extrapancreatic nerve plexus invasion (PL) accounted for 35.1%, 21.1%, and 15.6%, respectively. In terms of N classification, N0 accounted for 57.6% of the total (49/85). In terms of M classification, M0 accounted for 71.3% of the total (77/108). Histologically confirmed infiltration into the main pancreatic duct was seen in 19 (29.2%) of 65 patients.




FIGURE 1. Annual shifts in registration count of patients of ACC.

Tumor Markers

Figure 2 shows the results of CEA, CA19-9, and SPAN1 analyses for cases registered from 2001 to 2004. Mean values for the 3 markers were 7.6 ng/mL, 26.1 U/mL, and 34.8 U/mL, respectively. Although only 24 patients were registered, no significant correlation was noted between cancer stages and tumor markers, and only 1 case for each marker displayed extremely high levels.

Therapy Summary

In the present study, resection was performed on 88 patients (resection rate, 76.5%), palliative operation on 12 patients, and exploratory laparotomy on 4 patients. Details of resections were as follows: total pancreatectomy, 12.3%; pancreatoduodenectomy, 38.6%; distal pancreatectomy, 47.7%; and partial resection of the pancreas, 1.1% (Table 2).

Therapeutic Outcomes

Figure 3 shows the survival rate for resected and unresected cases. The 5-year survival rate for the 87 resected cases was 43.9%, with a median survival time (MST) of 41 months. The 5-year survival rate for unresected cases was 0%, with an MST of 3 months. A significant difference was identified between resected and unresected cases ($P < 0.0001$).

Figure 4 shows the survival rate for the 74 resected cases in relation to stage. The 5-year survival rate was 76.9% for stage II, 30.9% for stage III, with an MST of 18 months, 43.9% for stage IVa, with an MST of 41 months, and 25.1% for stage IVb, with an MST of 12 months. A significant difference in survival rate was identified between stages II and III.

Of the registered patients, information about recurrence was obtained from 11 patients. Sites of recurrence was liver (n = 8), peritoneum (n = 2), or local (n = 1). No metastases to lung, brain, or bone were identified.

DISCUSSION

A 20-year review by the JPS Pancreatic Cancer Registry^{2,3} included only 87 cases of ACC, and ACC accounted for 1 in every 119 cases of DCC, compared with

10,336 cases of DCC. In the literature, ACC accounts for about 1% to 2% of all pancreatic cancers,⁴⁻⁶ and only small-scale studies have examined ACC, such as Sumii et al⁶ (n = 6), Klimstra et al⁷ (n = 28), and Webb⁸ (n = 11).

In the present study, 67% of the 115 ACC patients were men. The male preponderance was consistent with previous studies conducted by Sumii et al⁶ and Klimstra et al⁷ (100% and 86%, respectively). Mean age is lower for ACC than for DCC, and patients younger than 30 years old were included in this study, as previously reported. A 9-year-old patient was reported by Osborne et al,⁹ and a 25-year-old patient was reported by Webb.⁸

Acinar cell carcinoma has so far been considered a cancer with poor prognosis, because, at the time of diagnosis, the tumor size is often large, vascular invasion is common, and hepatic and lymph node metastases occur early.^{5,10} The results of the present review show that T4 accounts for 55.3% of the total, but percentages of positive PV, A, and PL were low at 35.1%, 21.2%, and 15.6%, respectively. With DCC, T4 accounted for 74.8% of the total, and the percentages of positive PV, A, and PL were 59.6%, 39.9%, and 31.9%, respectively,^{2,3} indicating that vascular invasion is not necessarily common in ACC.

In regard with lymph node metastasis, N0 accounted for 57.6% of the total for ACC and 32.0% of the total for DCC, and M1 accounted for 28.7% of the total for ACC and 38.2% of the total for DCC. These findings suggest that the incidence of metastasis to lymph node and distant organs for ACC is lower than that for DCC.

TABLE 1. Pancreatic Acinar Cell Carcinoma Stage Among Registered Patients

JPS T classification system		Portal vein invasion	
T1	2 (2.1)	PV (-)	63 (64.9)
T2	23 (24.5)	PV (+)	34 (35.1)
T3	17 (18.1)	PV unknown	18
T4	52 (55.3)	Arterial invasion	
T unknown	21	A (-)	78 (78.8)
JPS N classification system		A (+)	21 (21.2)
N0	49 (57.6)	A unknown	16
N1	9 (10.6)	Extrapaneas nerve plexus invasion	
N2	13 (15.3)	PL (-)	65 (84.4)
N3	14 (16.5)	PL (+)	12 (15.6)
N unknown	30	PL unknown	38
JPS M classification system		Main pancreatic duct progress	
M0	77 (71.3)	MPD (-)	46 (70.8)
M1	31 (28.7)	MPD (+)	18 (27.7)
M unknown	7	MPD (borderline)	1 (1.5)
Stage		MPD unknown	50
I	2 (2.2)		
II	15 (16.9)		
III	12 (13.5)		
IVa	21 (23.6)		
IVb	39 (43.8)		
Stage unknown	26		

Values are given as n (%).




FIGURE 2. Relationship between acinar cell carcinoma stages and tumor markers for patients registered from 2001 to 2004.

Although invasion into the main pancreatic duct is reportedly lower for ACC than for DCC, which comes from the pancreatic ductal system,^{11,12} histologically confirmed invasion into the main pancreatic duct was seen in 29.2% of the registered ACC patients, suggesting that invasion into the main pancreatic duct is not rare in ACC. As far as preoperative pancreatocholangiography findings for ACC are concerned, nonspecific findings such as interruption of the pancreatic and bile ducts due to tumor compression are seen, and no distinct abnormal findings are present in many patients.^{12,13} Hence, even when interruption and blocking of pancreatic ducts is confirmed by preoperative pancreatocholangiography, ACC cannot be excluded, making ACC difficult to differentiate from DCC.

As far as tumor markers are concerned, levels of CEA, CA19-9, and SPAN1 are abnormally high in DCC, but low in ACC. However, although we can say that these low levels of tumor markers are characteristic of ACC, such levels are not useful for differential diagnosis. As for other tumor markers,

high levels of α -fetoprotein (AFP) are considered rare in pancreatic cancer,¹⁴⁻¹⁶ but according to a study by Shimizu et al,¹⁷ 11 of 41 pancreatic tumors displaying high levels of AFP were ACC (27%). Because ACC only accounts for a small percentage of overall pancreatic cancers, tumors showing high levels of AFP display increased frequency of ACC. Consequently, high AFP in pancreatic tumor may suggest ACC. Studies have also documented that ACC occasionally produces pancreatic enzymes such as lipase, amylase, and elastase I and is accompanied by systemic adiponecrosis, arthritis, or symptoms associated with functioning tumors.^{7,8,18} In the future, investigation of exocrine function and AFP will be necessary.

Previously, ACC has often been accompanied by widespread metastasis at the time of diagnosis, and surgery was not indicated, resulting in ACC being considered a carcinoma with extremely poor prognosis.^{4,7,8} However, because of recent advances in diagnostic imaging and surgical techniques, resection has been actively performed, and long-term survival has been reported.^{10,19-22} In terms of surgery, the same operations for DCC have been used, such as pancreatoduodenectomy and distal pancreatectomy, and surgical resection is the only option that can lead to long-term survival. The present results show that resection was

TABLE 2. Summary of Pancreatic Acinar Cell Carcinoma Therapy and Resection Techniques

Approach to treatment	
Resection	88 (76.5)
Palliative operation	12 (10.4)
Exploratory laparotomy	4 (3.5)
Non operation	10 (6.7)
Non operative autopsy	1 (0.9)
Operative procedure for resection in 88 patients	
Total pancreatectomy	11 (12.3)
Pancreatoduodenectomy	24 (27.3)
Pancreatoduodenectomy (subtotal)	1 (1.1)
Pylorus-preserving pancreatoduodenectomy	8 (9.1)
Substomach-preserving pancreatoduodenectomy	1 (1.1)
Distal pancreatectomy (tail)	5 (5.7)
Distal pancreatectomy (body-tail)	33 (37.5)
Distal pancreatectomy (subtotal)	3 (3.4)
Spleen-preserving distal pancreatectomy	1 (1.1)
Partial resection	1 (1.1)

Values are given as n (%).




FIGURE 3. Comparison of survival rate between resected and unresected acinar cell carcinoma.




FIGURE 4. Pancreatic acinar cell carcinoma: comparison of survival in relation to tumor stage among resected cases (n = 74).

performed in 76.5% of the total, much higher than in DCC where resection was performed in about 20% to 30% of the total. One reason for the high rate of resection is that vascular invasion and lymph node metastasis are less likely to occur, and invasion to the surrounding tissue is minimal. Among the reported resected cases, carcinoma was generally solitary and large but grew by compressing against the surrounding tissue and was often covered by a fibrous capsule. Acinar cell carcinoma reportedly often arises in the pancreatic head.

Chemotherapy and radiotherapy are other therapeutic options, but insufficient data have been accumulated on the efficacy of these therapies for ACC. Although some studies have reported that chemotherapy was ineffective in the treatment of ACC,^{5,7} various chemotherapies have been performed in other studies, such as systemic administration, intra-arterial injection, and intraperitoneal administration, and efficacy and long-term survival have been documented.^{10,15,16,22-24} Even when long-term survival cannot be achieved, tumor reduction was achieved and quality of life improved. Unlike DCC, ACC is often a hypervascular tumor, as are metastatic lesions,^{24,25} and as a result, antitumor agents readily reach the tumor. Because long-term survivors are all resected cases, surgical resection should be regarded as a treatment of choice. However, when ACC recurs after resection or is unresectable, chemotherapy may be a valid option, although therapeutic regimens and methods vary.

To the best of our knowledge, no reports have described radiotherapy alone, but several studies have documented the efficacy of radiochemotherapy.^{22,23} The radiosensitivity of ACC and efficacy of radiotherapy against ACC have not been clarified.

Like DCC, prognosis has been considered poor for ACC. Webb⁸ reported an MST of 4.3 months, and Cubilla and Fitzgerald⁴ reported a mean survival time of 7 months, but these studies described patients with unresectable ACC. Sumii et al⁶ studied 6 ACC patients, including 4 resectable cases, and reported a median survival of 358 days and 1-year survival of 50%. Klimstra et al⁷ described 28 ACC patients,

including 18 resectable cases, in which mean survival was 18.1 months and 1-year survival of 56.5%.

In the present study, the 5-year survival rate of 87 resected patients was 43.9%, with MST of 41 months, and these figures are much more favorable when compared with resected DCC patients with a 5-year survival rate of 12.2% and MST of 8.7 months.^{2,3} Among resected cases, survival rate for ACC in any stage was higher when compared with DCC, for which survival has been reported as stage I, 58.6%; stage II, 51.0%; stage III, 25.9%; stage IVa, 11.9%; and stage IVb, 2.8%.^{2,3} Also, the 5-year survival rate for stage IVb ACC was relatively favorable at 25.1%, with an MST of 12 months. These findings suggest that the survival rate is better for ACC than for DCC in any stage, and even in advanced cases, survival can be improved by resection. Surgery should thus be actively performed in the treatment of ACC. Although ACC has been considered a pancreatic cancer with poor outcomes, surgery appears to be associated with much better prognosis than anticipated.

CONCLUSIONS

The present study reviewed the clinical characteristics, treatment, and therapeutic outcomes of ACC. Compared with DCC, ACC has been considered a cancer with poor prognosis, but the present study showed that ACC can be resected in many cases and prognosis is greatly improved after resection. Surgery should thus be actively performed in the treatment of ACC. Although ACC is a rare tumor that cannot be easily differentiated from other common pancreatic tumors preoperatively, surgeons should keep ACC in mind. When a pancreatic tumor has proved to be ACC, surgeons should resect it actively using the same procedures as for DCC. Furthermore, even if ACC is unresectable or recurs postoperatively, chemotherapy should be considered. Future studies of more patients and establishment of multidisciplinary therapy centering on the role of surgery are warranted.

ACKNOWLEDGMENT

The authors thank the JPS members' cooperation for Pancreatic Cancer Registry.

REFERENCES

1. Japan Pancreas Society. *Classification of pancreatic carcinoma*. Tokyo, Japan: Kanehara Co, Ltd; 1996.
2. Japan Pancreas Society Registry Committee. *Suizou*. 2003;18:101-169. [in Japanese].
3. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. *Pancreas*. 2004;28:219-230.
4. Cubilla AL, Fitzgerald PJ. Acinar cell carcinoma. *Tumors of the Exocrine Pancreas*. Washington, DC: Armed Forces Institute of Pathology; 1984:208-212.
5. Kloppel G. Pancreatic, non-endocrine tumours. In: Kloppel G, Heitz PU, eds. *Pancreatic Pathology*. Edinburgh: Churchill Livingstone; 1984:79-113.
6. Sumii T, Funakoshi A, Ouchi J, et al. *Suizou*. 2001;16:455-459. [in Japanese].
7. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. *Am J Surg Pathol*. 1992;16:815-837.